title: Interaction of NK lysin, a peptide produced by cytolytic lymphocytes, with endotoxin.
abstract: NK lysin is a 9-kDa polypeptide that was originally isolated from porcine intestinal tissue based on its antibacterial activity. It is produced by cytolytic lymphocytes and is cytolytic against a number of different types of tumor cells. Here we report the binding of NK lysin to lipopolysaccharide (LPS) and its anti-LPS activity. NK lysin binds to matrix-coated LPS from Escherichia coli, Pseudomonas aeruginosa, and different strains of Salmonella enterica. Lipid A and polymyxin B inhibited the binding, demonstrating a preferential interaction of NK lysin with the lipid part of LPS. Chromium-labeled lymphoma cells were lysed by NK lysin, and LPS dose-dependently inhibited the cytolysis at equimolar amounts. In the same manner, NK lysin inhibited certain LPS-stimulated effects on mouse bone marrow cells as well as LPS binding to mouse granulocytes. These results suggest that NK lysin may be a another natural LPS-binding protein from lymphocytes that may participate in the endogenous defense response associated with elevated concentrations of LPS.
authors.affiliation: Immunochimie Analytique, URA CNRS 1961, Departement d'Immunologie, Institut Pasteur, Paris, France. mats.andersson@mbb.ki.se
authors.forename: M
authors.initials: M
authors.lastname: Andersson
authors.forename: R
authors.initials: R
authors.lastname: Girard
authors.forename: P
authors.initials: P
authors.lastname: Cazenave
mesh_terms: D000818:Animals; D003603:Cytotoxins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism / Q000494:pharmacology; D007275:Injections, Intravenous; D007694:Killer Cells, Natural / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000494:pharmacology; D051379:Mice; D008809:Mice, Inbred C3H; D010455:Peptides / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000494:pharmacology; D011485:Protein Binding; D011510:Proteolipids / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism* / Q000494:pharmacology; D011663:Pulmonary Surfactants / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism* / Q000494:pharmacology; D018805:Sepsis / Q000517:prevention & control; D013602:T-Lymphocytes, Cytotoxic / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D003603:Cytotoxins; D008070:Lipopolysaccharides; C093238:NK-lysin; D010455:Peptides; D011510:Proteolipids; D011663:Pulmonary Surfactants